0000000000278087

AUTHOR

Felice Iasevoli

showing 3 related works from this author

Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants

2018

Abstract Background Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants raises both efficacy, safety and tolerability concerns. The present study assesses the prevalence and clinical correlates of TEM in selected sample of Bipolar Disorder (BD) Type-II (BD-II) acute depression outpatients. Methods Post-hoc analysis of the clinical and psychopathological features associated with TEM among 91 BD-II depressed outpatients exposed to antidepressants. Results Second-generation antipsychotics (SGA) (p = .005), lithium (≤ .001), cyclothymic/irritable/hypert…

AdultMalemedicine.medical_specialtyBipolar DisorderAdolescentLithium (medication)media_common.quotation_subjectTreatment-emergent-maniaAntidepressantGastroenterologyYoung Adult03 medical and health sciencesBipolar Disorder (BD) Antidepressant Depression Treatment-emergent-mania0302 clinical medicineInternal medicineRecall biasOutpatientsmedicineHumansBipolar disorderAgedmedia_commonAntidepressant; Bipolar Disorder (BD); Depression; Treatment-emergent-mania; Clinical Psychology; Psychiatry and Mental Healthbusiness.industryDepressionMiddle Agedmedicine.diseaseBipolar Disorder (BD)Antidepressive Agents030227 psychiatryClinical PsychologyCross-Sectional StudiesTreatment OutcomeTolerabilityPsychiatry and Mental HealthAntidepressantDrug Therapy CombinationFemaleTemperamentmedicine.symptombusinessMania030217 neurology & neurosurgeryAntipsychotic AgentsPsychopathologymedicine.drug
researchProduct

Does the “Silver Bullet” Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients.

2016

Background:Though often perceived as a “silver bullet” treatment for bipolar disorder (BD), lithium has seldom reported to lose its efficacy over the time.Objective:The aim of the present study was to assess cases of refractoriness toward restarted lithium in BD patients who failed to preserve maintenance.Method:Treatment trajectories associated with re-instituted lithium following loss of achieved lithium-based maintenance in BD were retrospectively reviewed for 37 BD-I patients (median age 52 years; F:M=17:20 or 46% of the total) over an 8.1-month period on average.Results:In our sample only 4 cases (roughly 11% of the total, of whom F:M=2:2) developed refractoriness towards lithium after…

medicine.medical_specialtyPediatricsLithium (medication)EpidemiologyRefractory periodMaintenanceDiscontinuation03 medical and health sciences0302 clinical medicinemedicineClinical significanceBipolar disorderDiscontinuation Maintenance Refractoriness TolerancePsychiatryHigh rateSignificant differencemedicine.disease030227 psychiatryDiscontinuationPsychiatry and Mental healthProspective researchPsychologyRefractorineTolerance030217 neurology & neurosurgerymedicine.drug
researchProduct

Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews

2017

Introduction. A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews, nonetheless, aims at highlighting current essential information on the topic. Methods. Both published and unpublished systematic reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent authors inquiring PubMed/Cochrane/Embase/Scopus from inception u…

Genetics and Molecular Biology (all)Transtorno Bipolarmedicine.medical_specialtyBipolar DisorderImmunology and Microbiology (all)ConcordanceDrug profileAlternative medicineMEDLINElcsh:MedicineReview ArticleBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesLurasidone Hydrochloride0302 clinical medicineImmunology and Microbiology (all); Biochemistry Genetics and Molecular Biology (all)medicineBipolar DepressionHumansPsychiatryDrug ApprovalDepression (differential diagnoses)LurasidoneGeneral Immunology and Microbiologybusiness.industrylcsh:RGeneral Medicine030227 psychiatrySystematic reviewTolerabilityDepressãobusiness030217 neurology & neurosurgerymedicine.drugLurasidone
researchProduct